title: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries.
abstract: The protease and reverse transcriptase (RT) genes were studied in antiretroviral (ARV)-experienced and drug-naive HIV-1-infected individuals in Libreville, Gabon. We have shown, although on a limited number of samples that in 58% (11/19) of the patients, with a mean of 17.7 months of ARV drug experience, major mutations inevitably inducing resistances to ARV drugs were present. Resistance was mainly observed to the NRTIs (nucleoside analogue RT inhibitors). This high prevalence may reflect inappropriate ARV drug use. In order to avoid the rapid emergence of resistant viruses on a large scale in the developing world, it is important that the infrastructures necessary to monitor ARV treatment are also rapidly implemented in these countries and that clinicans are trained in the appropriate use of ARV drugs. A continuous surveillance of the circulation of ARV drug-resistant viruses must be organized to guide ARV treatment strategies and policies.
authors.affiliation: University of Montpellier I, Montpellier, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Vergne
authors.forename: Gabriel
authors.initials: G
authors.lastname: Malonga-Mouellet
authors.forename: Irene
authors.initials: I
authors.lastname: Mistoul
authors.forename: Roger
authors.initials: R
authors.lastname: Mavoungou
authors.forename: Helene
authors.initials: H
authors.lastname: Mansaray
authors.forename: Martine
authors.initials: M
authors.lastname: Peeters
authors.forename: Eric
authors.initials: E
authors.lastname: Delaporte
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003906:Developing Countries; D016049:Didanosine / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics; D005681:Gabon; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D016333:HIV Protease / Q000187:drug effects / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000187:drug effects / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D011159:Population Surveillance; D017410:Practice Guidelines as Topic; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D018119:Stavudine; D054303:HIV Reverse Transcriptase; D016333:HIV Protease; D016049:Didanosine